Edition:
United Kingdom

Opiant Pharmaceuticals Inc (OPNT.OQ)

OPNT.OQ on NASDAQ Stock Exchange Capital Market

15.51USD
16 Nov 2018
Change (% chg)

$-0.19 (-1.21%)
Prev Close
$15.70
Open
$15.59
Day's High
$16.47
Day's Low
$15.10
Volume
17,338
Avg. Vol
14,393
52-wk High
$35.49
52-wk Low
$12.75

Chart for

About

Opiant Pharmaceuticals, Inc., formerly Lightlake Therapeutics, Inc., is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was... (more)

Overall

Beta: -0.31
Market Cap(Mil.): $72.86
Shares Outstanding(Mil.): 2.03
Dividend: --
Yield (%): --

Financials

  OPNT.OQ Industry Sector
P/E (TTM): 14.34 31.23 33.59
EPS (TTM): 2.51 -- --
ROI: 231.11 15.57 15.05
ROE: 2,031.09 16.94 16.62

Consort, Opiant to develop nasal spray for opioid overdose treatment

Britain's Consort Medical Plc said on Monday it had agreed to develop a nasal spray for treating opioid overdoses with specialty pharmaceutical company Opiant Pharmaceuticals Inc.

10 Sep 2018

UPDATE 1-Consort, Opiant to develop nasal spray for opioid overdose treatment

Sept 10 Britain's Consort Medical Plc said on Monday it had agreed to develop a nasal spray for treating opioid overdoses with specialty pharmaceutical company Opiant Pharmaceuticals Inc.

10 Sep 2018

Consort and Opiant to work on nasal spray overdose treatment

Sept 10 Consort Medical Plc has agreed to develop a nasal spray for treating opioid overdoses with specialty pharmaceutical company Opiant Pharmaceuticals Inc .

10 Sep 2018

UPDATE 2-Emergent BioSolutions to buy Narcan maker Adapt Pharma

* Adapt partner Opiant soars in after-hours trading (Adds details and comment from conference call)

28 Aug 2018

Earnings vs. Estimates